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Many sequencing studies are now underway to identify the genetic causes for both Mendelian and complex traits. Via exome-
sequencing, genes harboring variants implicated in several Mendelian traits have already been identified. The underlying methodology
in these studies is a multistep algorithm based on filtering variants identified in a small number of affected individuals and depends
on whether they are novel (not yet seen in public resources such as dbSNP), shared among affected individuals, and other external
functional information on the variants. Although intuitive, these filter-based methods are nonoptimal and do not provide any
measure of statistical uncertainty. We describe here a formal statistical approach that has several distinct advantages: (1) it provides
fast computation of approximate p values for individual genes, (2) it adjusts for the background variation in each gene, (3) it allows
for incorporation of functional or linkage-based information, and (4) it accommodates designs based on both affected relative pairs
and unrelated affected individuals. We show via simulations that the proposed approach can be used in conjunction with the existing
filter-based methods to achieve a substantially better ranking of a gene relevant for disease when compared to currently used
filter-based approaches, this is especially so in the presence of disease locus heterogeneity. We revisit recent studies on three
Mendelian diseases and show that the proposed approach results in the implicated gene being ranked first in all studies, and approx-
imate p values of 106 for the Miller Syndrome gene, 1.0 3 104 for the Freeman-Sheldon Syndrome gene, and 3.5 3 105 for the
Kabuki Syndrome gene.Introduction
Spurred by recent advances in high-throughput se-
quencing technologies, sequencing studies for varied
Mendelian and complex traits are currently underway.
Such studies will provide an unprecedented view of the
genetic variation, rare and common, that influences the
risk of these diseases. Genes for several Mendelian diseases
have already been identified1–3 via exome-sequencing of
a small number of affected individuals and additional
information from public resources such as dbSNP and the
1000 Genomes Project.
The large number of genetic variants in the human
genome and the low population frequency of the majority
of these variants create challenges for the computational
and statistical analysis of these data. In particular, tradi-
tional testing strategies based on individual variant testing
can have low power, and new statistical methods that
aggregate information across multiple variants in a genetic
region have been proposed.4–13
For Mendelian diseases, traditional methods for gene
mapping range from candidate gene studies (where candi-
dates were selected based, for example, on functional
similarity to already established genes, and in many situa-
tions their exons were sequenced in a small number of
subjects) to positional cloning strategies (where small
regions discovered via linkage analysis were followed-up
with denser genotyping that led to the identification of
haplotypes thought to harbor causal mutations). Recently,1Department of Biostatistics, Columbia University, New York, NY 10032, USA
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exome sequencing data on a small number of (mostly
unrelated) affected individuals to identify the genes con-
taining disease variants in several Mendelian traits.1–3
Unlike traditional linkage methods, the underlying gene
could be identified directly and by using unrelated
subjects. More precisely, in each case the relevant gene
was identified via a filter-based methodology, where
variants identified in cases were checked for novelty (not
identified before), functionality (e.g., nonsynonymous
variants), and sharing among affected (and possibly
related) individuals. Such an approach is intuitive and
reasonable; however, from an inferential perspective it
has several disadvantages including: (1) it does not pro-
duce any measure of statistical uncertainty (e.g., gene-level
p values), making it unfeasible to assess consistency with
the null hypothesis; (2) it does not adjust for background
variation in each gene, therefore allowing large genes to
rank high on the basis of their size alone; and (3) it does
not properly account for the different levels of variant
sharing expected among relatives of different types, which
can affect the rank of the genes. Although the filter-based
approach can take into account external information
such as functional predictions or linkage scores, such infor-
mation needs to be provided in a dichotomized fashion
(e.g., linkage or no linkage) rather than original scores (or
transformations thereof).
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of the filter-based approach and show applications to
simulated data and recent studies for three Mendelian
traits. For these previously published Mendelian studies,
we show that the proposed approach ranks the gene
relevant for disease first in all three studies and assigns
significant p values to the respective genes.
We assume the disease mutations in Mendelian diseases
are rare, as is strongly suggested by the data available
on Mendelian mutations.14 We also assume that disease
mutations are deleterious, a reasonable assumption for
Mendelian disorders.Material and Methods
We start by reviewing the filter-based approach that is cur-
rently being used to map genes harboring disease variants
for Mendelian traits from sequence data. Then we propose a
weighted sum statistic and an analytical approximation of the
p value for a gene. We then discuss an omnibus method that
combines this weighted sum approach with the currently-used
filter-based method to achieve a more sensible gene ranking
procedure.Filter-Based Approach
The filter-based approach is based on computing for each gene
a statistic equal to the number of affected individuals that are
carriers of at least one nonsynonymous variant that is novel,
that is, not seen in controls.1 For unrelated affected individuals,
computing this statistic is straightforward. Let G be a gene of
interest andMU be the number of novel variant positions observed
in a set of A affected individuals sequenced at gene G. Let Xij be
the coded genotype (i.e., the number of the minor allele) for
affected individual i % A at novel variant position j % MU. Then
for each affected individual i, we calculate the load (or burden)
of novel nonsynonymous variants as:
Li ¼
XMU
j¼1
wjXij;
where wj is 1 for nonsynonymous variant and is 0 otherwise. Then
the filter-based method is based on the following statistic:
Sfilter ¼
XA
i¼1
IfLi>0g; (Equation 1)
where I($) is an indicator function. Genes are then ranked
according to the value of Sfilter.
For affected relative pairs and Mendelian diseases, it is reason-
able to assume that both affected individuals in a pair share the
disease variant. If each pair of affected relatives is treated as
a unit, the score for each unit (i.e., the equivalent of I{Li>0} above)
is taken to be 1 if there is at least one novel, nonsynonymous
variant in geneG shared between both relatives, and is 0 otherwise.
However, this definition fails to account for the different levels
of expected sharing among relatives of different types. Ideally,
one would like to assign a higher score if two cousins share such
a variant versus two siblings. Later we discuss such an alternative
scoring scheme.
As the number of sequenced controls increases, restricting atten-
tion to only the novel variants runs the risk of disregarding rare702 The American Journal of Human Genetics 89, 701–712, Decembdisease mutations that are in fact present in control individuals
as well (possibly because of reduced penetrance and/or a recessive
mode of inheritance). A simple extension of the filter-based
approach is to also consider variants that have a frequency in
controls less than some threshold, say 0.01, rather than only the
novel ones. We refer to this approach as Filter-R (all rare variants
are included), and the existing filter-based approach based on
novel variants only is referred to as Filter-N.Weighted Sum Statistic for Mendelian Traits
We describe here a weighted sum statistic that resembles statistics
that have been proposed before for case-control designs.6
However, unlike existing weighted sum statistics, for the proposed
statistic (1) an approximate analytical p value can be calculated for
each gene, and (2) both affected relative pairs and unrelated
affected individuals can be accommodated.
Let G be a gene of interest and M be the number of rare variant
positions observed in a set of individuals (both affected and
unaffected) sequenced at gene G. We assume for now that all
individuals are unrelated. A rare variant is defined as a variant
with a population frequency less than some prespecified
threshold, e.g., 0.01. The optimal threshold is not known and
necessarily depends on the underlying frequency spectrum for
disease mutations in Mendelian diseases. However, extensive
data available on the frequency spectrum for Mendelian muta-
tions suggest that the total mutation frequency is <<1% for
most Mendelian diseases.14 For each rare variant position j,
with j % M, let T (j) be the total number of variants in affected
individuals (note that this corresponds to an additive model).
One simple statistic we can define is:
S ¼
XM
j¼1
TðjÞ:
Moreover, incorporation of external weights such as those from
Polyphen15 or SIFT16 can be done easily. For example,
Sw ¼
XM
j¼1
wjTðjÞ;
where wj is the weight for variant j, which can be any real
positive number (derived independently of the data). For
example, if only nonsynonymous variants are to be included,
then wj ¼ 1 for such variants and is 0 otherwise. A similar weight-
ing scheme works if only variants that are not in dbSNP are to be
considered.
Let Na be the total number of chromosomes in affected individ-
uals, and Nu be the corresponding number for controls. For
variant j let bf j be the estimated frequency based on controls. If
we assume that the underlying frequency distribution of the
variants in a region can be approximated by Beta (a,b), then we
estimate fj by:
bf j ¼ xj þ aNu þ aþ b;
where xj is the observed number of occurrences of the minor
allele in controls at variant position j (The parameters a and
b can be estimated from data available on controls with standard
maximum likelihood estimation.17 We also note that results
are robust to the choice of a and b, especially as Nu becomes
large.). If we assume for now that the rare variants under consid-
eration are in linkage equilibrium, then we show in Appendix Aer 9, 2011
(Expectation and Variance of T(j) and Expectation and Variance
of Sw) that:
bEðSwÞ¼XM
j¼1
wjNabf j and dVarðSwÞ ¼XM
j¼1
w2j Na

Na  1
Nu
þ 1
bf j1 bf j:
In the general case when variants are allowed to be correlated,
a suitable variance estimator has also been derived (Expectation
and Variance of Sw).
We use the following gamma-based approximation for the
probability density function of the weighted sum statistic of
Poisson-like random variables (Table A6; see also Fay and Feuer18):
PnullðaÞ ¼ PðSwRaÞ ¼ 1Q

abwequiv;
bEðSwÞbwequiv

; (Equation 2)
where bwequiv ¼ dVarðSwÞ=bEðSwÞ and Q is the incomplete gamma
function: Qða; xÞ ¼ 1=GðaÞ RNx et ta1dt:
This approximation becomes very accurate as the observed
number of variants M in a region increases. It can however be
slightly conservative when M is small (Table A6).
Only Novel Variants in Cases are Considered
Previous studies on several Mendelian traits1–3 have used public
resources such as dbSNP and 1000 Genomes Project data as well
as sequence data on a small number of controls to filter out vari-
ants that are common and only keep those that are novel (do
not appear in these existing databases). This is indeed a reasonable
approach if disease mutations are assumed to be very rare and
highly penetrant.We canmodify our weighted sum statistic above
as follows:
Snovelw ¼
XMU
j¼1
wjTðjÞ;
where MU is the number of novel variants in affected individuals.
Note that MU is a subset of M and that EðSnovelw Þ%EðSwÞ and
VarðSnovelw Þ%VarðSwÞ. In order to calculate EðSnovelw Þ and VarðSnovelw Þ
one would need to estimate the number of novel variants in cases
based on the observed variants in controls, and both parametric
and nonparametric methods can be applied to obtain such esti-
mates.17,19 However, it can be difficult to obtain accurate estimates
on the number of novel variants in a gene if only a small number
of variants is observed in controls, as would be the case for many
genes of small to moderate length. Therefore, we use the same
gamma-based approximation as in Equation 2 to obtain an upper
bound on the p value for this scenario.
In what follows we refer to the weighted sum approach with all
rare variants as WS-R and to the above approach with only the
novel variants as WS-N.
Affected-Relative Pairs
For Mendelian diseases data on affected relatives, for example
affected siblings or affected cousins, might be available. It
would be desirable to extend both the filter-based approach and
the weighted sum approach discussed above to be able to handle
relative pairs. A simple solution adopted in the current filter-
based approach is to score each pair of affected relatives as 1 if
they share at least one novel and nonsynonymous variant and
is 0 otherwise. A potential weakness of such a scoring scheme
is that it fails to account for the different levels of expected
sharing among relatives of different types. In particular, we would
like to assign a higher score when such sharing happens between
more distant relatives, for example cousins, compared with
siblings.The AmericanIn Ionita-Laza and Ottman20 we have developed such a scoring
scheme. Namely, for a pair of relatives, we derive an effective
number of variants in the pair, that is, the number of variants
at a fixed segregating or variant position adjusted for the
familial correlation. We have denoted this number by keff and
showed there that for a pair of relatives keff can be calculated
as follows:
keff ¼
8<
:
logf ½4f 4þ 4f 2ð1 44þ 4d42Þ; if both relatives carry
a rare variant
1; if only one of the two relatives carries a rare variant
0; if neither of the two relatives carries a rare variant
where f is the frequency of the variant at the given position, 4 is
the kinship coefficient; d is 0 if the two relatives can share
a maximum of one allele identical by descent (e.g., first cousins)
and 1 if they can share two alleles identical by descent (e.g.,
siblings).
When two heterozygous individuals are unrelated, 4 ¼ 0, and
we obtain the expected result that keff ¼ 2. For identical twins
4 ¼ 0.5, d ¼ 1, and keff ¼ 1. For two sibs, when f ¼ 0.01 we obtain
keff ¼ 1.17. Similarly for two second cousins, keff ¼ 1.76. These
and other examples are summarized in Table A1. With this
scoring scheme, the filter-based approach can be modified to
assign higher scores to sharing among cousins compared with
siblings.
It is also possible to extend the weighted sum approach to take
into account data on affected relatives in addition to unrelated
affected individuals. For a variant position and a pair of relatives,
instead of the observed number of variants we use the effective
number keff defined above. Then for variant position j we replace
T(j), the total number of variants at position j in the affected
individuals, with Teff(j), and the weighted sum statistic is corre-
spondingly defined as:
Sw ¼
XM
j¼1
wjTeff ðjÞ:
As for the scenarios with only unrelated individuals, we
derive a gamma-based approximation for the distribution of Sw
(Expectation and Variance of Sw When Affected Individuals Are
Related).
For Mendelian diseases, it is reasonable to assume that affected
relatives within the same family are likely to share the disease
mutation. The approach discussed above can be modified easily
to reflect this assumption by setting keff to be zero unless both rela-
tives share a variant (that can be, for example, nonsynonymous
and novel). More precisely,
keff ¼
8<
:
log2f ½4f 4þ 4f 2ð1 44þ 4d42Þ; if both relatives carry
a rare variant
0; if only one of the two relatives carries a rare variant
0; if neither of the two relatives carries a rare variant
This is the default setting in our handling of affected relatives,
and the one illustrated in the examples that follow.
Joint-Rank Approach
We describe here how the weighted sum approach above can be
combined with the currently-used filter-based method to produce
an overall better ranking for the gene(s) containing disease vari-
ants in a study. Both approaches discussed in the previous
sections attempt to quantify the increase in rare variant burden
in affected individuals, although in slightly different ways. TheJournal of Human Genetics 89, 701–712, December 9, 2011 703
Table 1. Summary of Methods Discussed in Text
Approach Description
WS-R weighted sumwith all rare variants (e.g., minor allele
frequency [MAF]% 0.01)
WS-N weighted sum with only novel variants
(not seen before)
Filter-R filter-based approach with all rare variants
(e.g., MAF % 0.01)
Filter-N filter-based approach with only novel variants
(not seen before)
Joint-Rank-R for each gene: the average of the ranks from
approach WS-R and Filter-R
Joint-Rank-N for each gene: the average of the ranks from
approach WS-N and Filter-N
Table 2. Type 1 Error for the Case-Control Design
Aa Ub
a
104 103 102 5 3 102
WS-R
5 100 1.5 3 104 6.0 3 104 4.0 3 103 1.7 3 102
500 1.3 3 104 7.0 3 104 5.0 3 103 2.1 3 102
1000 1.1 3 104 5.7 3 104 5.0 3 103 2.1 3 102
10 100 1.0 3 104 4.0 3 104 3.0 3 103 1.6 3 102
500 1.2 3 104 7.1 3 104 4.8 3 103 2.3 3 102
1000 1.1 3 104 8.0 3 104 5.0 3 103 2.3 3 102
WS-N
5 100 7.8 3 105 3.0 3 104 1.5 3 103 6.7 3 103
500 2.6 3 105 7.4 3 105 4.3 3 104 3.0 3 103
1000 2.1 3 105 1.2 3 104 2.9 3 104 1.1 3 103
10 100 3.3 3 105 1.4 3 104 1.1 3 103 6.1 3 102
500 7.0 3 106 5.2 3 105 2.5 3 104 2.0 3 103
1000 1.3 3 105 3.0 3 105 1.1 3 104 8.6 3 104
a Number of unrelated affected individuals.
b Number of unrelated unaffected individuals.weighted sum approach aggregates information across all affected
individuals and adjusts for the underlying variation in controls,
but does not always distinguish whether the variants that enter
the calculation of Sw occur in many or just a few of the individ-
uals. On the contrary, the existing filter-based approach essen-
tially exploits the information on the number of affected individ-
uals that carry at least one novel variant but fails to distinguish
whether variants occur recurrently at the same position, or
different positions, and does not take into account the number
of novel variants an individual carries, unlike the weighted sum
approach.
For the purpose of ranking genes, we propose to combine the
two approaches to calculate for each gene a combined rank, hence-
forth called the Joint-Rank, that represents the average of the
ranks from the weighted sum and filter-based approaches. For
a gene that contains variants implicated in disease, both ranks
should be high, and the Joint-Rank approach might lead to an
overall better ranking of that gene. The filter-based rank is not
adjusted for the background variation, and hence the Joint-Rank
can be viewed as adjusting the filter-based rank for the length of
the gene and the background variation in each gene.
The various approaches discussed in this section are summa-
rized in Table 1.Software
Software implementing the proposed approaches is avail-
able freely on I.I.-L.’s website.Results
Next, we investigated via simulations the properties of the
proposed approaches. We also used real high-coverage
sequence data on 310 control individuals randomly
selected from the large collection of unaffected individuals
that have been sequenced as part of the American
Recovery and Reinvestment Act (ARRA) Autism Project
(see Sequence Data for more details on these data) to illus-
trate applications to three Mendelian disease examples
recently reported in the literature: Miller Syndrome2
[MIM 264750], Freeman-Sheldon Syndrome1 [MIM
193700], and Kabuki Syndrome3 [MIM 147920].704 The American Journal of Human Genetics 89, 701–712, DecembSimulated Data
We first used simulations to investigate the underlying
properties of the proposed approaches. We simulated 10
independent genomic regions each 1 Mb long under a
coalescent model by using the software package COSI.21
Themodel used in the simulation was the calibratedmodel
for the European population and was an option available
in the COSI package. A total of 10,000 haplotypes were
generated for each region. We then randomly sampled
small subregions of the size of individual genes. The size
of each gene was sampled from the length distribution of
real exonic regions (as available from the refGene table;
see Web Resources).
Type 1 Error
We evaluated the type 1 error of the proposed approaches
for several different scenarios, including two different
designs: (1) case-control and (2) affected sib pairs and unre-
lated controls. The results for the case-control design are
shown in Table 2. We show there that the proposed
gamma-based approximation is valid and leads to a good
control of the type 1 error when rare variants (not neces-
sarily novel) are considered.
When only novel variants (i.e., not seen in a set of
independent controls) are considered, the approximation
can be very conservative. Despite this conservativeness,
because the magnitude of the effect at genes with variants
implicated in Mendelian diseases is expected to be large,
the approximation is expected to be powerful for such
effects. Permutation-based methods can be employed for
the genes with smallest p values to obtain better approxi-
mations for the p values (see Permutation Testing).er 9, 2011
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Figure 1. TheMedian Rank, with Novel-Variants Only, of a Gene
with Variants Implicated in Disease in Genome Scans with 20,000
Genes, with Gene Length Sampled from the Real Gene Length
Distribution
One thousand such genome scans are simulated. Two to six of 10
affected individuals are assumed to carry a novel disease mutation
in the implicated gene (with fewer mutations for larger number of
controls). The following methods are compared: WS-N, Filter-N,
and Joint-Rank-N.Similar results hold for data sets containing affected
relative pairs (Table A2).
Gene Ranking
We investigated here the performance of the various
approaches as measured by the overall ranking of the
gene relevant for disease in a genome scan with 20,000
genes. A genome scan was simulated by sampling 20,000
regions with region length selected from the gene (exonic)
length distribution in refGene table. The genes were
sampled independently from the ten 1 Mb regions we
have simulated. We assumed ten affected individuals and
a number of controls between 100 and 500. One gene
at random was selected, and a small number of affected
individuals (between two and six) were assumed to each
carry a different novel disease mutation in that gene. We
simulated 1,000 such genome scans, and calculated the
median rank for the implicated gene across the 1,000 simu-
lations.
We show in Figure 1 that the Joint-Rank-N approach
outperforms both the WS-N and the Filter-N methods
in terms of the rank assigned to the implicated gene.
The performance of the filter-based approach decreases
with increasing genetic heterogeneity, and it is in these
situations that a formal approach such as the weighted
sum method discussed in this paper becomes particularly
necessary.The AmericanFiltering out variants that have been seen before could
become problematic in the near future as the number of
sequenced controls continues to grow because disease
variants can potentially be present in controls as well (in
the case of reduced penetrance and/or a recessive mode
of inheritance). The extension of the filter-based approach
to include rare variants rather than only novel variants
(i.e., Filter-R) does not perform very well, especially as
the number of affected individuals that carry a disease
mutation at a disease locus decreases (Figure A1). In such
situations the proposed weighted sum approach (WS-R)
alone is expected to perform better. We also note here
that the performance of all methods improves substan-
tially as the number of sequenced controls increases.
Results for affected sib pairs are shown in Figure A2 and
are similar to those for the case-control design.
Applications to Three Mendelian Diseases
For these applications, we used real high-coverage
sequence data with spiked-in mutations to resemble the
original disease studies as closely as possible. In particular,
we assumed that the same number of affected individuals
as in the original studies are carriers of novel nonsynony-
mous disease mutations, and these mutations are artifi-
cially added to the corresponding gene for each study
above and beyond the existing variation in our real data.
We also disregarded variants with a known rs number by
simply setting their weights to 0. The next set of results
are based on these spike-in data sets.
Miller Syndrome
In Ng et al.2 the authors performed exome-sequencing of
four affected individuals, two siblings and two unrelated
affected individuals, with Miller Syndrome. All four
affected individuals were compound heterozygotes for
novel and nonsynonymous mutations in one gene,
DHODH [MIM 126064], and the two siblings shared the
disease mutations. Because the sequence data available to
us contained only unrelated individuals, we emulated
the original study by using data on only three unrelated
individuals as cases and 300 unrelated individuals as
controls; all individuals were part of the same exome-
sequencing study (Sequence Data). For the implicated
gene DHODH we made the additional assumption that
each of the three affected individuals was compound
heterozygote for unique mutations in this gene.
In Figure 2 we plot the p values (WS-N) for all genes, as
well as the value of the filter-based statistic (i.e., the number
of affected individuals carriers of novel nonsynonymous
variants). With only three affected individuals, we identify
gene DHODH as the leading gene, with an approximate
p value of 106 (WS-N). The permutation p values are
3.0 3 107 for both WS-R and WS-N.
Freeman-Sheldon Syndrome
For the Freeman-Sheldon syndrome example, Ng et al.1
performed exome-sequencing of four unrelated affected
individuals. Two different novel and nonsynonymous
variant positions in the same gene, MYH3 [MIM 160720],Journal of Human Genetics 89, 701–712, December 9, 2011 705
0
1
2
3
4
5
6
-lo
g1
0(
P
)
Chromosome
DHODH
0
1
2
3
4
5
6
MS - Gene P-values
# Carriers
-lo
g1
0(
P
)
0
1
2
3
4
5
6
1 2 3
DHODH
MS - P vs. # Carriers
0
1
2
3
4
5
-lo
g1
0(
P
)
Chromosome
MYH3
0
1
2
3
4
5
FSS - Gene P-values
# Carriers
-lo
g1
0(
P
)
0
1
2
3
4
5
1 2 3 4
MYH3
FSS - P vs. # Carriers
0
1
2
3
4
5
6
-lo
g1
0(
P
)
Chromosome
MLL2
0
1
2
3
4
5
6
KS - Gene P-values
# Carriers
-lo
g1
0(
P
)
0
1
2
3
4
5
6
2 4 6 8 10
MLL2
KS - P vs. # Carriers
Applications to three Mendelian Diseases
0
0
0
Figure 2. Applications to Three Mende-
lian Diseases: Miller Syndrome,
Freeman-Sheldon Syndrome, and Kabuki
Syndrome
Left: The p values (WS-N) for 19,811 genes
surveyed (Manhattan plot). Right: For
each gene the number of affected individ-
uals that are carriers of novel disease vari-
ants and the gene p value are shown.were detected in all four individuals. Three individuals had
a mutation at the first variant position, whereas the fourth
individual had a mutation at the second variant position.
Based on our spike-in data set, the resulting approximate
p value (WS-N) in this case is 1.03 104. This was the high-
est ranked gene in the study (Figure 2). The permutation p
values are 5.7 3 105 for WS-R and 6.0 3 107 for WS-N.
Kabuki Syndrome
For the Kabuki Syndrome example, exome-sequencing was
performed in ten unrelated affected individuals (Ng et al.3).
Nine different novel and nonsynonymous mutations in
gene MLL2 [MIM 602113] were identified in the ten
affected individuals. Based on our spike-in data set, the re-
sulting approximate p value (WS-N) is 3.5 105, and again
this is the highest ranked gene (Figure 2). The permutation
p values are 3.4 3 106 for WS-R and 4.0 3 107 for WS-N.
Results for these three Mendelian diseases are summa-
rized in Table 3 and Table A7.Discussion
Recent studies have shown how genes harboring variants
implicated in Mendelian diseases can be identified with
whole-exome sequence data for a small number of affected
individuals. The underlying approach is based on filtering
variants based on novelty, functionality, and sharing
among multiple affected individuals. Such filter-based
approaches are intuitive and powerful for Mendelian
diseases but suffer from several shortcomings. Notable
among them are (1) the lack of statistical uncertainty706 The American Journal of Human Genetics 89, 701–712, December 9, 2011assessment (e.g., in the form of
p values) and (2) the lack of adjust-
ment for the background variation
in each gene, so that large genes can
rank high on the basis of their size
alone. We have shown here that
such a filter-based approach can be
complemented by a formal statistical
procedure that has several distinct
advantages: (1) it evaluates statistical
significance by calculating approxi-
mate p values, (2) it can handle both
related and unrelated affected indi-
viduals, (3) it can incorporate exter-
nal weights about the functionality
of variants or linkage-based scores,and importantly, (4) it adjusts for background variation
so that more variable regions do not rise to the top based
on noise alone. The resulting procedure leads to an overall
better ranking of the relevant gene and allows for untying
genes that otherwise have the same number of affected
individuals that carry a novel mutation in the gene. The
proposed method is particularly useful (compared with
the filter-based approach) when there is locus heteroge-
neity and more complex inheritance, a scenario likely to
happen as more and more Mendelian diseases are being
studied.22
We have investigated two distinct scenarios: one that
considers all rare variants in the population, regardless of
whether they have been seen before or not (WS-R); and
a second scenario where only novel variants in cases are
included (WS-N). We have derived a gamma-based approx-
imation for the null distribution of the weighted sum
statistic WS-R and have shown that this approximation is
good. Also, we have shown that the same approximation
can be used for WS-N to derive an upper bound on the p
value (although more precise approximations can be ob-
tained by random permutations, especially on the genes
with the smallest p values). Via applications to both simu-
lated and real data, we have shown that a combination of
the weighted sum approach and the filter-based approach,
a procedure we call Joint-Rank, provides a more robust way
to rank genes in Mendelian diseases compared with filter-
based approaches alone. In particular, the Joint-Rank
approach adjusts for the background variation in each
gene (as does the weighted sum approach) and at the
same time favors genes with a larger number of affected
Table 3. Summary Results for the Applications to Three
Mendelian Traits
Syndrome
Gene
Length (kb)
Data Set
MOIa
P valueb
(WS-N)Ac Ud
Miller 16.0 3 300 CH 1.0 3 106
Freeman-Sheldon 28.7 4 300 D 1.0 3 104
Kabuki 36.3 10 300 D 3.5 3 105
a Mode of Inheritance: compound heterozygote (CH) or dominant (D).
b Analytical p value.
c Number of unrelated affected individuals.
d Number of unaffected individuals.individuals that are carriers of novel variants (as does the
filter-based approach).
Throughout most of our examples, we have assumed
that causal variants are novel and hence not present in
unaffected individuals. Under such a scenario, the optimal
approach is indeed to only consider novel variants.
However, if causal variants could be present in unaffected
individuals (for example, for a recessive mode of inheri-
tance, or reduced penetrance scenarios), the weighted
sum approach WS-R should also be considered. This is
particularly important as the number of control exomes
available increases when even very rare variants can be
identified in control individuals. The availability of a large
number of sequenced controls will be important, because,
as we have shown, the power of the proposed approach
increases with the number of controls.
We revisited recent exome-sequencing studies on several
Mendelian diseases and showed how the approach works
concretely in these examples. The proposed approach
produced significant p values for each of the genes that
harbor disease variants for the three Mendelian traits while
properly adjusting for the background variation in each
gene, as estimated from exome-sequencing data available
to us for 300 controls. Because of the lack of even
modest-sized sequence data sets in the past, the filter-based
approach used a variety of variant databases to filter out
already discovered variants, including dbSNP and 1000
Genomes Project data. With the proposed approach, it is
still possible to use these databases to filter out variants
by simply setting the weights for variants in the databases
to 0, and this is especially useful when the number of
controls available is rather small. For our own examples,
we have presented results based on a relatively small
number of controls (i.e., 300); however, increasing the
number of controls will naturally lead to smaller p values
and improved overall ranking for the gene harboring
disease variants.
As with any association study, good experimental design
is essential. The validity of the p values obtained from the
weighted sum approach, and of the Joint-Rank procedure
overall, is contingent on having a control data set that is
comparable to the affected individuals for both ethnic
background as well as sensitivity and specificity for variant
detection. Other potential issues, such as hidden related-The Americanness among individuals, can lead to an inflated type 1
error. Principal component analysis or mixed-model
methods can be used to adjust for relatedness of subjects
by extending the current method to a regression-frame-
work, such as sequence kernel association test.13 Adjust-
ment for covariates, when available, is also straightforward
in such a framework.
One strength of the proposed weighted sum approach
is that the p values can be obtained in an analytical
fashion. This fact makes the proposed approach to be
computationally very fast compared to a permutation-
based procedure, and also allows inclusion of affected
relative pairs, situations where resampling-based proce-
dures are nontrivial. Our applications to the three Mende-
lian disease examples each took ~45 seconds on a regular
desktop.
The proposed methods implicitly assume an additive
model for the effect of mutations at a position. This model
is optimal for additive, and expected to be powerful for
dominant, compound heterozygous and recessive modes
of inheritance.
For Mendelian diseases, results from previous linkage-
based scans might be available. In that case, Roeder
et al.23 proposed an exponential weighting scheme,
whereby linkage scores are translated into weights that
can be used to weight the gene-level p values calculated
with the proposed approach, as in a weighted hypothesis
testing procedure.24
In summary, we have discussed an analytic framework to
identify genes that contain variants implicated in Mende-
lian diseases and have shown that it performs well in simu-
lations and applications to previous exome-sequencing
studies for three Mendelian traits.Appendix A
Expectation and Variance of Sw for Unrelated Cases
Expectation and Variance of T(j). We assume we have
sequenced Na / 2 affected individuals, and Nu / 2 unaf-
fected individuals. For an observed variant position j, letbf j be the estimated frequency of fj based on Nu chromo-
somes. Then we use the following to estimate the expected
value of T(j).
bEðTðjÞÞ ¼ Nabf j:
For the variance, we have:
dVarðTðjÞÞ ¼ VarETðjÞ j bf j þ EVarðTðjÞÞ j bf j
¼ Var

Nabf j þ ENabf j1 bf j
¼ N2a
bf j1 bf j
Nu
þNabf j NaEbf 2j 
¼ Na

Na  1
Nu
þ 1
bf j1 bf j:Journal of Human Genetics 89, 701–712, December 9, 2011 707
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Figure A1. TheMedian Rank, with All Rare Variants Considered.
of a Gene with Variants Implicated in Disease in Genome Scans
with 20,000 Genes, with Gene Length Sampled from the real
Gene Length Distribution
One thousand such genome scans are simulated. Two to six of ten
affected individuals are assumed to carry a novel disease mutation
in the implicated gene. The following methods are compared:
WS-R, Filter-R, and Joint-Rank-R.
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Figure A2. TheMedian Rank of a Gene with Variants Implicated
in Disease in Genome Scans with 20,000 Genes and Gene Length
Sampled from the Real Gene Length Distribution
One thousand genome scans are simulated. Two to four of five
affected sib pairs (ASP) are assumed to share a novel disease muta-
tion in the gene. The following methods are compared: WS-N,
Filter-N, and Joint-Rank-N.Expectation and Variance of Sw. We recall here that for
each gene we calculate the following weighted sum
statistic:
Sw ¼
XM
j¼1
wjTðjÞ:
Then bEðSwÞ ¼PMj¼1wjbEðTðjÞÞ. For the variance of Sw we
have:
dVarðSwÞ ¼XM
j¼1
w2j
dVarðTðjÞÞ þ X
1%jsj0%M
wjwj0 dCovðTðjÞ;Tðj0ÞÞ:
The covariance can be estimated as follows.25 Let Ve be
the M3M empirical variance estimator with
yjj0 ¼ A=N
PN
i¼1ðXij  EðXijÞÞðXij0  EðXij0 ÞÞ, where N ¼ A þ U
is the total number of individuals (affected and unaf-
fected). Let D be the M3M diagonal matrix with
djj ¼ dVarðTðjÞÞ. Also, we define an adjusted variance
matrix: VA ¼ D1=2½DiagðVeÞ1=2VeDiagðVeÞ1=2D1=2. Then
an estimate for Var (Sw) is
P
j;j0VA½j; j0:
Expectation and Variance of Sw When Affected
Individuals Are Related
Expectation and Variance for T(j). We show here how to
derive the expected value and variance of Teff at a variant
position when affected relatives are considered. Let A be708 The American Journal of Human Genetics 89, 701–712, Decembthe total number of affected relative pairs (of same type).
If f is estimated based on Nu chromosomes, then we can
get for
bETeff	 ¼ Akeff j24bf 4þ 4bf ð1 24Þ	:
dVarTeff	 ¼ A2
keff j244þ 4ð1 24Þ2 bf ð1 bf Þ
Nu
þ A,
keff j24bf 4þ 4bf ð1 24Þ
where
keff j2y log2f
h
4f 4þ 4f 2
1 44þ 4d42i:
Note that above we replace f by bf when calculating
keffj2. Through simulation experiments we have shown
that there is small variability in the values of keffj2 for any
fixed value of bf . If one assumes that f follows, for example,
a Beta(0.1 þ x, 10 þ N – x) where x is the observed number
of occurrences of the minor allele in controls, and N is the
number of control chromosomes, then we show in Table
A3 that the variability in keff is quite small.
To assess the covariance between Teff at two different
positions, we need to know the joint distribution of geno-
types at two positions in two relatives. Lange26 has derived
the relative-to-relative transition probabilities for two
linked genes, and wemake use of these transition probabil-
ities and the observed genotype distribution at two posi-
tions in unrelated controls to derive the joint distributioner 9, 2011
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Figure A3. Q-Q plot showing distribution of Teff versus Poisson
[E (Teff)]
One hundred ASPs and 500 controls are simulated for a total of
30,000 simulations.
Table A1. The Effective Number of Variants at a Rare Variant
Position in Two Related Heterozygous Individuals as Defined in the
Text
Relationship 4 keff
Identical twins 1 / 2 1.00
Parent-child 1 / 4 1.17
Sibs 1 / 4 1.17
Half sibs 1 / 8 1.34
Uncle-nephew 1 / 8 1.34
First cousins 1 / 16 1.50
First cousins once removed 1 / 32 1.64
Second cousins 1 / 64 1.76
Unrelated individuals 0 2.00
4 is the kinship coefficient. Results for f ¼ 0.01 are shown.
Table A2. Type 1 Error for the Sib Pair Design
Aa Ub
a
104 103 102 5 3 102
WS-R
5 100 1.7 3 104 8.0 3 104 4.7 3 103 2.0 3 102
500 1.0 3 104 7.4 3 104 5.5 3 103 2.6 3 102in relatives that we need. We then use a gamma-based
approximation for the weighted sum of Poisson random
variables.
We claim here that the distribution of Teff under the null
hypothesis of no association with disease can be approxi-
mated by an overdispersed Poisson distribution with
mean
PA
i¼1E½keffðiÞ, and an index of dispersion very close
to 1. It is easy to verify this claim by simple simulation
experiments. We have simulated data sets of affected sib
pairs and controls at one single variant position of
frequency 0.001 % f % 0.01. For each data set, we calcu-
late Teff assuming (1) the true value of f and (2) the esti-
mated value of f from controls. We report the mean and
variance for Teff(f) and Teffðbf Þ based on 10,000 random
simulations as well as the correlation between Teff(f) and
Teffðbf Þ. Results are shown in Table A4. For more distant
relatives, such as first and second cousins, we only report
the theoretical mean and variance for Teff(f) (Table A5). As
shown, the theoretical and empirical results match very
well. There is a slight inflation in the variance over
the mean for sib pairs and when f ¼ 0.01 (dispersion
index < 1.06), although this inflation disappears for
more distant relatives. In Figure A3 we also show the1 3 5
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Figure A4. Q-Q plots showing the distributions of observed p
values versus expected p values for three Mendelian diseases
Analytical p values are based on WS-R.
The Americandistribution of Teff against a Poisson with the same mean
for a scenario with 100 affected sib pairs and 500 controls
and f ¼ 0.005.
Gamma-Based Approximation for a Sum of Weighted
Poisson Random Variables
We have done some simple calculations in R to assess
the accuracy of the gamma-based approximation for the
weighted sum of Poisson random variables. We assume M
Poisson random variables are included, and for each
a weight wi is chosen from U(0,1). The results for different
values for M are shown in Table A6.1000 1.4 3 104 7.0 3 104 4.9 3 103 2.5 3 102
10 100 1.0 3 104 5.0 3 104 3.8 3 103 1.8 3 102
500 1.1 3 104 9.8 3 104 6.0 3 103 2.7 3 102
1000 1.5 3 104 9.9 3 104 5.9 3 103 2.7 3 102
WS-N
5 100 1.0 3 104 4.5 3 104 2.2 3 103 8.0 3 103
500 2.7 3 105 2.7 3 104 4.9 3 104 2.4 3 103
1000 2.4 3 105 5 3 105 3.0 3 104 1.5 3 103
10 100 4.9 3 105 2.5 3 104 1.4 3 103 6.7 3 103
500 2.0 3 105 1.0 3 104 3.8 3 104 1.7 3 103
1000 4.9 3 105 1.0 3 104 2.9 3 104 1.4 3 103
a Number of affected sib pairs.
b Number of unrelated unaffected individuals.
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Table A3. Mean and Standard Deviation for keffj2 Assumingbf ¼ 0:005 0:01 and f Is Sampled from the Corresponding Posterior
Distribution
Number of Controls Mean Standard Deviation
0.01
100 1.17 0.03
500 1.17 0.01
1000 1.17 0.01
0.005
100 1.14 0.03
500 1.14 0.01
1000 1.14 0.01
Table A5. Theoretical Results for Teff
f N
Theoretical
m var
Siblings
0.01 5 0.156 0.161
0.001 0.016 0.016
First cousins
0.01 5 0.191 0.194
0.001 0.019 0.019
Second cousins
0.01 5 0.197 0.196
0.001 0.019 0.020Quantile-Quantile Plots for Three Mendelian Diseases
In addition to theManhattan-type plots in Figure 2 we also
show here the Quantile-Quantile (Q-Q) plots (Figure A4).
Note that the observed p values refer to analytical p values
calculated based on WS-R. We remove genes with little
information, namely those genes with no observed variant
in affected individuals. The resulting distribution of p
values is, however, not uniform (0,1) because of the bias
induced by selecting only genes with at least one variant
in cases. Therefore, we only consider observed p values
that are less than 0.2.Permutation Testing
It is possible to obtain empirical p values for the weighted
sum approach by random permutations of case/control
status for each of the three Mendelian diseases considered.
For the permutation approach the usual procedure is to
randomly reassign case/control status to the individuals
in the data set and then calculate the p value from the
gamma-based approximation (Equation 2 in text). The
empirical p value is calculated as the proportion of
permuted data sets for which the gamma-based p value isTable A4. Simulation Results for Teff
Nsibs Ncontrols
f bf
Cora
Theoretical
bm dvar bm dvar m var
f ¼ 0.01
5 100 0.152 0.163 0.152 0.163 0.999915 0.156 0.161
500 0.153 0.151 0.153 0.151 0.999968 0.156 0.161
1000 0.162 0.168 0.162 0.168 0.999986 0.156 0.161
f ¼ 0.001
5 100 0.017 0.018 0.017 0.018 0.999864 0.016 0.016
500 0.014 0.015 0.014 0.015 0.999984 0.016 0.016
1000 0.016 0.017 0.016 0.017 0.999985 0.016 0.016
a Correlation between Teff(f) and Teffðbf Þ.
710 The American Journal of Human Genetics 89, 701–712, Decembat most as large as the p value observed in the original
data. Results for the three Mendelian disease are shown
in Table A7.
Sequence Data
To illustrate applications to real sequence data, we used
exome-level data on 310 control individuals randomly
selected from the large collection of unaffected individ-
uals that have been sequenced as part of the ARRA
Autism Project (AAP). The AAP involves whole-exome
sequencing of 1,000 autism cases, 1,000 controls, and
several hundred trios. Whole-exome sequencing of
controls was carried out at the Broad Institute and at Bay-
lor College of Medicine with standard approaches.
Following quality control (QC), variants were called
with several approaches (including the Genome Analysis
Toolkit27), and variant call files with all variants and rele-
vant QC metrics were made available to us. For our appli-
cations we considered data on 310 randomly chosen
control individuals.Acknowledgments
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